Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
All content for Being a Life Sciences Leader is the property of Life Sciences Pennsylvania and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
Join us as Senator Robinson discusses his key role in passing SB954 - which provides Pennsylvanians better access to personalized treatments following a diagnosis of cancer and other specific diseases through biomarker testing and precision medicine. Learn about Senator Robinson's journey as the bill's prime sponsor, the collaborative efforts to get it unanimously passed in the Senate and what this milestone means for patients and Pennsylvania's healthcare system.
Being a Life Sciences Leader
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
